Chenodeoxycholic Acid
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Chenodeoxycholic Acid |
| DrugBank ID | DB06777 |
| Brand Names (EU) | Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.79% |
Approved Indication (EMA)
Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | cholelithiasis | 99.79% | DL |
| 2 | homozygous familial hypercholesterolemia | 99.57% | DL |
| 3 | brain small vessel disease 1 with or without ocular anomalies | 99.43% | DL |
| 4 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 99.40% | DL |
| 5 | obsolete familial combined hyperlipidemia | 99.34% | DL |
| 6 | obsolete hyperuricemia (disease) | 99.27% | DL |
| 7 | hypouricemia, renal | 98.89% | DL |
| 8 | diabetic nephropathy | 98.76% | DL |
| 9 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | 97.80% | DL |
| 10 | familial isolated hypoparathyroidism due to impaired PTH secretion | 97.51% | DL |
| 11 | Lesch-Nyhan syndrome | 97.48% | DL |
| 12 | biotin metabolic disease | 97.09% | DL |
| 13 | renal tubular acidosis | 96.89% | DL |
| 14 | acromesomelic dysplasia, Campailla Martinelli type | 96.73% | DL |
| 15 | Dahlberg-Borer-Newcomer syndrome | 96.71% | DL |
| 16 | vitamin deficiency disorder | 96.71% | DL |
| 17 | congestive heart failure | 96.54% | DL |
| 18 | craniofacial conodysplasia | 96.44% | DL |
| 19 | pseudo-von Willebrand disease | 96.34% | DL |
| 20 | primary release disorder of platelets | 96.20% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.